AR037299A1 - Uso para eltratamiento de la enfermedad de reflujo gastroesofagico - Google Patents

Uso para eltratamiento de la enfermedad de reflujo gastroesofagico

Info

Publication number
AR037299A1
AR037299A1 ARP020104319A ARP020104319A AR037299A1 AR 037299 A1 AR037299 A1 AR 037299A1 AR P020104319 A ARP020104319 A AR P020104319A AR P020104319 A ARP020104319 A AR P020104319A AR 037299 A1 AR037299 A1 AR 037299A1
Authority
AR
Argentina
Prior art keywords
treatment
cannabinoid receptor
gastroesophagic
regurgitation
inhibition
Prior art date
Application number
ARP020104319A
Other languages
English (en)
Spanish (es)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR037299A1 publication Critical patent/AR037299A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ARP020104319A 2001-11-23 2002-11-11 Uso para eltratamiento de la enfermedad de reflujo gastroesofagico AR037299A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0103936 2001-11-23

Publications (1)

Publication Number Publication Date
AR037299A1 true AR037299A1 (es) 2004-11-03

Family

ID=20286096

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020104319A AR037299A1 (es) 2001-11-23 2002-11-11 Uso para eltratamiento de la enfermedad de reflujo gastroesofagico

Country Status (20)

Country Link
US (1) US7358245B2 (cg-RX-API-DMAC7.html)
EP (1) EP1453497A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005511632A (cg-RX-API-DMAC7.html)
KR (1) KR20050044582A (cg-RX-API-DMAC7.html)
CN (1) CN1610542A (cg-RX-API-DMAC7.html)
AR (1) AR037299A1 (cg-RX-API-DMAC7.html)
AU (1) AU2002353700A1 (cg-RX-API-DMAC7.html)
BR (1) BR0214319A (cg-RX-API-DMAC7.html)
CA (1) CA2466916A1 (cg-RX-API-DMAC7.html)
HU (1) HUP0402080A3 (cg-RX-API-DMAC7.html)
IL (1) IL161748A0 (cg-RX-API-DMAC7.html)
IS (1) IS7272A (cg-RX-API-DMAC7.html)
MX (1) MXPA04004774A (cg-RX-API-DMAC7.html)
NO (1) NO20042613L (cg-RX-API-DMAC7.html)
NZ (1) NZ532844A (cg-RX-API-DMAC7.html)
PL (1) PL369402A1 (cg-RX-API-DMAC7.html)
RU (1) RU2280443C2 (cg-RX-API-DMAC7.html)
TW (1) TW200407110A (cg-RX-API-DMAC7.html)
WO (1) WO2003043619A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200403785B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0415851A (pt) * 2003-10-24 2007-01-02 Solvay Pharm Gmbh utilizações médicas de compostos que apresentam atividade antagonìstica de cb1 e tratamento de combinação envolvendo os referidos compostos
WO2005060971A1 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of reflux-related diseases
SE0303490D0 (sv) * 2003-12-19 2003-12-19 Astrazeneca Ab New use V
RU2007119315A (ru) 2004-10-25 2008-11-27 Зольвай Фармасьютиклз Гмбх (De) Фармацевтические композиции, содержащие антагонисты каннабиноидного рецептора св1 и открыватели калиевых каналов, предназначенные для лечения сахарного диабета типа i, ожирения и связанных с ними состояний
EP1827393A4 (en) * 2004-12-09 2012-04-18 Insys Therapeutics Inc AT ROOM TEMPERATURE, STABLE DRONABINOL FORMULATIONS
US20080112895A1 (en) * 2006-08-04 2008-05-15 Insys Therapeutics Inc. Aqueous dronabinol formulations
WO2009020666A1 (en) * 2007-08-06 2009-02-12 Insys Therapeutics Inc. Oral cannabinoid liquid formulations and methods of treatment
US20110172305A1 (en) * 2007-10-02 2011-07-14 Ester Fride Endocannabinoids for Enhancing Growth and Development in Infants
US20090208588A1 (en) * 2008-02-19 2009-08-20 Roger Wayne Brown GERD carbohydrate compositions
CN103588672A (zh) * 2013-10-28 2014-02-19 史克勇 一种治疗癌性疼痛的药物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2735774B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
US6017919A (en) * 1996-02-06 2000-01-25 Japan Tobacco Inc. Compounds and pharmaceutical use thereof
US5939429A (en) * 1997-09-30 1999-08-17 Virginia Commonwealth University Cardiovascular uses of cannabinoid compounds
CA2340445A1 (en) * 1998-05-04 1999-11-11 The University Of Connecticut Novel analgesic and immunomodulatory cannabinoids
CA2330681C (en) * 1998-05-29 2008-08-26 Andrea Giuffrida Control of pain with endogenous cannabinoids
GB9923738D0 (en) 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
IL132661A (en) * 1999-10-31 2008-11-26 Raphael Mechoulam Agonists specific for peripheral cannabinoid receptors
SE9904507D0 (sv) * 1999-12-09 1999-12-09 Astra Ab New compounds
KR100604742B1 (ko) * 2000-06-15 2006-07-26 쉐링 코포레이션 트롬빈 수용체 길항제
AUPR118000A0 (en) * 2000-11-02 2000-11-23 Amrad Operations Pty. Limited Therapeutic molecules and methods
FR2816938B1 (fr) * 2000-11-22 2003-01-03 Sanofi Synthelabo Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant
US20020077322A1 (en) * 2000-12-15 2002-06-20 Ayoub George S. Protection of neurons against glutamate-induced damage in glaucoma and other conditions

Also Published As

Publication number Publication date
EP1453497A1 (en) 2004-09-08
HUP0402080A2 (hu) 2005-02-28
TW200407110A (en) 2004-05-16
CA2466916A1 (en) 2003-05-30
AU2002353700A1 (en) 2003-06-10
CN1610542A (zh) 2005-04-27
ZA200403785B (en) 2005-05-19
NZ532844A (en) 2005-12-23
BR0214319A (pt) 2004-11-03
RU2004114843A (ru) 2005-05-27
JP2005511632A (ja) 2005-04-28
RU2280443C2 (ru) 2006-07-27
WO2003043619A1 (en) 2003-05-30
WO2003043619A8 (en) 2005-03-17
HUP0402080A3 (en) 2008-03-28
US20040266861A1 (en) 2004-12-30
NO20042613L (no) 2004-08-13
PL369402A1 (en) 2005-04-18
IS7272A (is) 2004-05-19
IL161748A0 (en) 2005-11-20
MXPA04004774A (es) 2004-07-30
KR20050044582A (ko) 2005-05-12
US7358245B2 (en) 2008-04-15

Similar Documents

Publication Publication Date Title
ECSP044992A (es) Inhibidores de la alquín-aril fosfodiesterasa-4
ES2547336T3 (es) Composición tópica para su uso para el tratamiento de enrojecimiento inducido por rosácea
CO5090908A1 (es) Procedimiento para administrar peptidos insulinotropicos
NI201100062A (es) Inhibidores de las enzimas de proteína cinasa activadas por mitógeno p38.
AR048588A1 (es) Uso de inhibidores de la fosfodiesterasa de tipo iii (pde iii) para la reduccion del tamano del corazon en mamiferos que padecen insuficiencia cardiaca
ES2572454T3 (es) Tratamiento de enfermedades mediadas por los linfocitos T
BR0314603A (pt) Uso de inibidores da sìntese de citoquina para o tratamento de distúrbios de olhos secos
AR052221A1 (es) Metodo para el tratamiento de la enfermedad poliquistosis renal
BRPI0311275A2 (pt) "composições de fenofibrato estáveis para administração oral, bem como uso das mesmas"
CY2607B2 (en) Synergistic combination of pde inhibitors and adenylate cyclase agonists or guanylcyclyse agonists
CR8102A (es) Derivados de pirazolo- quinazolina, procedimiento para preparacion y su uso como inhibidores de quinasa
AR044923A1 (es) Imidazoquinolinas sustituidas con sulfonamida
BRPI0413695A (pt) derivados de naftiridina substituìda como inibidores do fator inibidor da migração de macrófagos e seu uso no tratamento de doenças humanas
NO20030929L (no) Guanidinobenzamider som MC4-R agonister
SE9800836D0 (sv) New Compounds
CO5160321A1 (es) Novedosas composiciones de tipranavir y ritonavir
AR067347A1 (es) Combinacion antihelmintica
CL2008003938A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
AR109263A2 (es) Composición que comprende moxidectina
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
AR039633A2 (es) Uso de un compuesto tipo cabergolina para preparar un medicamento para el tratamiento de la fibromialgia y el sindrome de fatiga cronica
AR024998A1 (es) Nuevos retinoides para el tratamiento del enfisema
AR008908A1 (es) Uso de loratadina y un descongestivo para preparar un medicamento para mejorar la funcion pulmonar de un paciente que padece asma
AR030516A1 (es) Uso de una combinacion de salmeterol y fluticasona
AR018505A1 (es) COMPOSICIoN FARMACÉUTICA ANTIHISTAMíNICA CON UN INHIBIDOR DE LA P-GLICOPROTEíNA Y EL USO DE DICHA COMPOSICIoN PARA LA FABRICACIoN DE MEDICAMENTOS PARA AUMENTAR LA BIODISPONIBILIDAD DE DICHO ANTIHISTAMíNICO.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal